SANTHERA Trademark

Trademark Overview

On Wednesday, October 19, 2022, a trademark application was filed for SANTHERA with the United States Patent and Trademark Office. The USPTO has given the SANTHERA trademark a serial number of 97638731. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, August 28, 2024. This trademark is owned by Santhera Pharmaceuticals (Schweiz) AG. The SANTHERA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of ocular, inflammatory and pulmonary diseases, but not in the field of oncology and rheumatoid arthritis
santhera

General Information

Serial Number97638731
Word MarkSANTHERA
Filing DateWednesday, October 19, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, August 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 4, 2023

Trademark Statements

Description of MarkThe mark consists of the word "santhera" appearing in lower case lettering with two arched lines appearing alongside and to the left of the word.
Goods and ServicesPharmaceutical preparations for the treatment of ocular, inflammatory and pulmonary diseases, but not in the field of oncology and rheumatoid arthritis
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, November 3, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSanthera Pharmaceuticals (Schweiz) AG
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPratteln 4133
CH
Party NameSanthera Pharmaceuticals (Schweiz) AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPratteln 4133
CH

Trademark Events

Event DateEvent Description
Saturday, October 22, 2022NEW APPLICATION ENTERED
Thursday, October 27, 2022TEAS VOLUNTARY AMENDMENT RECEIVED
Thursday, October 27, 2022TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Thursday, November 3, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 4, 2022NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, March 2, 2023ASSIGNED TO EXAMINER
Thursday, March 9, 2023NON-FINAL ACTION WRITTEN
Thursday, March 9, 2023NON-FINAL ACTION E-MAILED
Thursday, March 9, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, May 24, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, May 24, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 24, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 26, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 14, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, July 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 29, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 30, 2024TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, January 30, 2024DIVISIONAL REQUEST RECEIVED
Tuesday, January 30, 2024SOU EXTENSION 1 FILED
Tuesday, January 30, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 12, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, February 15, 2024DIVISIONAL PROCESSING COMPLETE
Thursday, February 15, 2024SOU EXTENSION 1 GRANTED
Friday, February 16, 2024CORRECTED NOA E-MAILED
Friday, February 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 28, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, August 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 28, 2024SOU EXTENSION 2 FILED
Wednesday, August 28, 2024SOU EXTENSION 2 GRANTED

Related Keywords

santhera field oncology rheumatoid arthritis diseases pulmonary preparations treatment ocular inflammatory